Sweden's Bactiguard Q3 revenue rises on partnership with Becton, Dickinson & Company

By Reuters News


Overview

  • Sweden MedTech firm's Q3 revenue rose 21% yr/yr on strong partnership demand

  • Adjusted EPS turned positive to SEK 0.25 from a loss last yr

  • Company cites Becton, Dickinson partnership as key contributor to Q3 performance


Outlook

  • Company expects continued positive growth within its license business, driven by market traction

  • Bactiguard sees long-term outlook for Wound Management as positive, citing market dynamics and Hydrocyn aqua expansion

  • Company remains committed to disciplined cost management while investing in long-term growth priorities


Result Drivers

  • PARTNERSHIP GROWTH - Co said revenues from Becton, Dickinson partnership grew more than 30% and were main contributor to Q3 performance

  • ROYALTY INCREASE - Double-digit growth in royalties from Zimmer Biomet partnership driven by higher product sales and market demand

  • LEAN OPERATIONS - Co said lean business model helped translate revenue growth into strong underlying earnings in Q3


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

SEK 58.40 mln

SEK 55 mln (1 Analyst)

Q3 Adjusted EPS

SEK 0.25

Q3 Net Income

SEK 7.30 mln

Q3 EBITDA

SEK 17.50 mln

Q3 Operating Cash Flow

SEK 14 mln

Q3 Operating Profit

SEK 6.80 mln


Analyst Coverage

  • Wall Street's median 12-month price target for Bactiguard Holding AB is SEK21.50, about 49.3% above its October 21 closing price of SEK14.40


Reuters Recommended Reads

  • Oct 21 - Sweden's Getinge Q3 organic sales rise 2.1%

  • Oct 21 - Medical gear maker Getinge beats Q3 profit estimates on pricing, product mix

  • Oct 21 - Sweden's AddLife beats Q3 net sales expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.